What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?

CCUR > College of Business > Department of Business Administration & Graduate Institute of International Business Administration > periodical articles > Item 987654321/48895

Please use this identifier to cite or link to this item: https://irlib.pccu.edu.tw/handle/987654321/48895

Title:	What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?
Authors:	Wang, WK (Wang, Wei-Kang) Lu, WM (Lu, Wen-Min) Kweh, QL (Kweh, Qian Long) Truong, HTN (Hoang Tu Nhi Truong)
Contributors:	國企系
Keywords:	INTELLECTUAL PROPERTY-RIGHTS MARKET VALUE OPERATING PERFORMANCE CONTEXTUAL VARIABLES FIRM VALUE INNOVATION EFFICIENCY PRODUCTIVITY INVESTMENT IMPACT
Date:	2020-07
Issue Date:	2020-12-11 15:21:09 (UTC+8)
Abstract:	This paper investigates how patents and research and development (R&D) spikes affect the corporate performance of 863 firm-year observations of U.S. biopharmaceutical companies. First, a dynamic data envelopment analysis model is adopted to evaluate the performance of the U.S. biopharmaceutical companies. Then, ordinary least squares regression is used to explore the effects of three patent-related variables (patent counts, citations, and claims) and R&D spikes on corporate performance. This study finds positive impacts of patent counts, citations, and claims on corporate performance. In addition, the results show that R&D spikes have negative contemporaneous effects and time-lagged effects on corporate performance.
Relation:	MANAGERIAL AND DECISION ECONOMICS 卷冊: 41 期: 5 頁數: 762-770
Appears in Collections:	[Department of Business Administration & Graduate Institute of International Business Administration ] periodical articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	137	View/Open

View Licence